血管肽对大鼠移植动脉硬化的影响。
Effects of angiopeptin on transplant arteriosclerosis in the rat.
作者信息
Akyürek M L, Wanders A, Aurivillius M, Larsson E, Funa K, Fellström B C
机构信息
Department of Pathology, University Hospital, Uppsala, Sweden.
出版信息
Transpl Int. 1995;8(2):103-10. doi: 10.1007/BF00344419.
The influence of the somatostatin analogue angiopeptin on transplant arteriosclerosis was investigated using two aortic transplantation rat models. One was characterized by ischemia/reperfusion-induced changes in syngeneic transplants while immunologically induced changes dominated in the other allogeneic model. Angiopeptin, 100 micrograms/kg per day, was administered continuously until the sacrifice of the rats after 8 weeks. No additional immunosuppression was used in either model. An image analysis system was used to quantify the intimal and medial thicknesses of the grafts. In the syngeneic grafts, the intimal thickness was less than 50% of that of control grafts (P < 0.05), but no difference was seen in the allogeneic model. The expression of selected cells, TGF-beta s, and PDGF and PDGF alpha-receptors was detected immunohistochemically and displayed a similar picture in control and angiopeptin-treated grafts in both models. We conclude that angiopeptin has no clear immunosuppressive properties but may counteract ischemia-induced transplant arteriosclerosis.
使用两种主动脉移植大鼠模型研究了生长抑素类似物血管活性肠肽对移植动脉硬化的影响。一种模型的特征是同基因移植中缺血/再灌注诱导的变化，而在另一种异基因模型中，免疫诱导的变化占主导。每天以100微克/千克的剂量持续给予血管活性肠肽，直至8周后处死大鼠。两种模型均未使用额外的免疫抑制。使用图像分析系统量化移植物的内膜和中膜厚度。在同基因移植物中，内膜厚度小于对照移植物的50%（P<0.05），但在异基因模型中未观察到差异。通过免疫组织化学检测所选细胞、转化生长因子-β、血小板衍生生长因子（PDGF）和PDGFα受体的表达，在两种模型的对照移植物和血管活性肠肽处理的移植物中显示出相似的情况。我们得出结论，血管活性肠肽没有明显的免疫抑制特性，但可能抵消缺血诱导的移植动脉硬化。
Zotero 插件